Lurasidone as a potential therapy for bipolar disorder

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 1521-1529

  Woo, Young Sup ^a   Wang, Hee Ryung ^a   Bahk, Won Myong ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Acute depression; Bipolar disorder; Lurasidone; Metabolic

Indexed keywords

EID: 84885467441     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S51910     Document Type: Review

References (47)

1. Keck PE, McElroy SL, Arnold LM. Bipolar disorder. Med Clin North Am. 2001;85(3):645-661, ix.
2. Akiskal HS. The bipolar spectrum: research and clinical perspectives. Encephale. 1995;21 Spec No 6:3-11. French.
3. Angst J. Epidemiology of the bipolar spectrum. Encephale. 1995;21 Spec No 6:37-42. French.
4. Bebbington P, Ramana R. The epidemiology of bipolar affective disorder. Soc Psychiatry Psychiatr Epidemiol. 1995;30(6):279-292.
5. Lee S, Ng KL, Tsang A. A community survey of the twelve-month prevalence and correlates of bipolar spectrum disorder in Hong Kong. J Affect Disord. 2009;117(1-2):79-86.
6. Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. 2nd ed. New York, NY: Oxford University Press; 2007.
7. Beyer JL. An evidence-based medicine strategy for achieving remission in bipolar disorder. J Clin Psychiatry. 2008;69 Suppl 3:31-37.
8. Bowden CL, Perlis RH, Thase ME, etal. Aims and results of the NIMH systematic treatment enhancement program for bipolar disorder (STEP-BD). CNS Neurosci Ther. 2012;18(3):243-249.
9. Judd LL, Akiskal HS, Schettler PJ, etal. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-537.
10. Denicoff KD, Smith-Jackson EE, Disney ER, Suddath RL, Leverich GS, Post RM. Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p). J Psychiatr Res. 1997;31(5):593-603.
11. Paykel ES, Abbott R, Morriss R, Hayhurst H, Scott J. Sub-syndromal and syndromal symptoms in the longitudinal course of bipolar disorder. Br J Psychiatry. 2006;189:118-123.
12. Judd LL, Akiskal HS, Schettler PJ, etal. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60(3):261-269.
13. Dion GL, Tohen M, Anthony WA, Waternaux CS. Symptoms and functioning of patients with bipolar disorder six months after hospitalization. Hosp Community Psychiatry. 1988;39(6):652-657.
14. Judd LL, Akiskal HS, Schettler PJ, etal. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005;62(12):1322-1330.
15. Martinez-Aran A, Vieta E, Torrent C, etal. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord. 2007;9(1-2):103-113.
16. MacQueen GM, Marriott M, Begin H, Robb J, Joffe RT, Young LT. Subsyndromal symptoms assessed in longitudinal, prospective follow-up of a cohort of patients with bipolar disorder. Bipolar Disord. 2003;5(5):349-355.
17. Angst J. The course of affective disorders. II. Typology of bipolar manic-depressive illness. Arch Psychiatr Nervenkr. 1978;226(1):65-73.
18. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry. 1995;152(11):1635-1640.
19. Keller MB, Lavori PW, Coryell W, Endicott J, Mueller TI. Bipolar I: a five-year prospective follow-up. J Nerv Ment Dis. 1993;181(4): 238-245.
20. Keck PE Jr, McElroy SL. Redefining mood stabilization. J Affect Disord. 2003;73(1-2):163-169.
21. Bauer M, Ritter P, Grunze H, Pfennig A. Treatment options for acute depression in bipolar disorder. Bipolar Disord. 2012;14 Suppl 2:37-50.
22. Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry. 1995;152(3):379-384.
23. Strakowski SM, Sax KW, McElroy SL, Keck PE, Hawkins JM, West SA. Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. J Clin Psychiatry. 1998;59(9):465-471.
24. Caccia S, Pasina L, Nobili A. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatr Dis Treat. 2012;8: 155-168.
25. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65(2):189-210.
26. Risbood V, Lee JR, Roche-Desilets J, Fuller MA. Lurasidone: an atypical antipsychotic for schizophrenia. Ann Pharmacother. 2012;46(7-8):1033-1046.
27. Meneses A. Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004in autoshaping Pavlovian/instrumental learning task. Behav Brain Res. 2004;155(2):275-282.
28. Guscott M, Bristow LJ, Hadingham K, etal. Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. Neuropharmacology. 2005;48(4):492-502.
29. McIntyre RS, Cha DS, Alsuwaidan M, McIntosh D, Powell AM, Jerrell JM. A review of published evidence reporting on the efficacy and pharmacology of lurasidone. Expert Opin Pharmacother. 2012;13(11): 1653-1659.
30. Ishibashi T, Horisawa T, Tokuda K, etal. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171-181.
31. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009;18(11): 1715-1726.
32. Calabrese JR, Loebel A, Cucchiaro J, etal. Lurasidone adjunctive to lithium or valproate for the treatment of bipolar I depression: results of the 6-week, double-blind, placebo-controlled PREVAIL-1study. Neuropsychopharmacology. 2012;38:S132. Available from: http://www.nature.com/npp/journal/v38/n1s/index.html. Accessed July 20, 2013.
33. Loebel A, Cucchiaro J, Silva R, etal. Lurasidone monotherapy for the treatment of bipolar depression: results of the 6-week, double-blind, placebo-controlled PREVAIL-2study. Neuropsychopharmacology. 2012;38:S422-S423. Available from: http://www.nature.com/npp/journal/v38/n1s/index.html. Accessed July 21, 2013.
34. Yatham LN, Kennedy SH, Parikh SV, etal. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1-44.
35. Hirschfeld RMA, Cucchiaro J, Pikalov A, etal. Effect of lurasidone monotherapy or adjunctive therapy on anxiety symptoms in patients with bipolar I depression. Neuropsychopharmacology. 2012;38: S423-S424. Available from: http://www.nature.com/npp/journal/v38/n1s/index.html. Accessed July 21, 2013.
36. Potkin SG, Ogasa M, Cucchiaro J, Loebel A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res. 2011;132(2-3):101-107.
37. Nakamura M, Ogasa M, Guarino J, etal. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829-836.
38. Meltzer HY, Cucchiaro J, Silva R, etal. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957-967.
39. Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013;147(1):95-102.
40. Citrome L, Cucchiaro J, Sarma K, etal. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27(3):165-176.
41. Cucchiaro J, Pikalov A, Ogasa M. Safety of lurasidone: pooled analysis of five placebo-controlled trials in patients with schizophrenia. Int J Neuropsychopharmacol. 2010;13(Suppl 1):217.
42. Citrome L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad Med. 2011;123(2): 153-162.
43. Samalin L, Garnier M, Llorca PM. Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag. 2011;7: 239-250.
44. Ehret MJ, Sopko M, Lemieux T. Focus on lurasidone: a new atypical antipsychotic for the treatment of schizophrenia. Formulary. 2010;45(10):313-317.
45. Kantrowitz JT, Citrome L. Lurasidone for schizophrenia: what's different? Expert Rev Neurother. 2012;12(3):265-273.
46. Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther. 2012;29(10):815-825.
47. Ketter TA, Cucchiaro J, Silva R, etal. Lurasidone for bipolar I depression: effects on quality of life and functioning. Neuropsychopharmacology. 2012;38:S169-170. Available from: http://www.nature.com/npp/journal/v38/n1s/index.html. Accessed July 21, 2013.